MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/75/0.1/20.09.24

MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/75/0.1/20.09.24 Stock

DE000ME58671

Real-time Bid/Ask 03:13:05 2024-06-27 EDT
0.016 ^EUR / 0.04 ^EUR	+64.71%

Current month	+54.55%
1 month	+54.55%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart MORGAN STANLEY PLC/CALL/BRISTOL-MYERS SQUIBB/75/0.1/20.09.24

Latest news about BRISTOL-MYERS SQUIBB COMPANY

2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	06-26	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-26	0.017	0.00%
24-06-25	0.017	0.00%
24-06-24	0.017	+21.43%
24-06-21	0.014	0.00%
24-06-20	0.014	-6.67%

Delayed Quote Börse Stuttgart

Last update June 26, 2024 at 12:33 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	Morgan Stanley
WKN	ME5867
ISIN	DE000ME58671
Date issued	2023-12-13
Strike	75 $
Maturity	2024-09-20 (86 Days)
Parity	10 : 1
Emission price	0.07 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.039 €
Lowest since issue	0.005 €
Delta	0.06x
Omega	8.122
Premium	77.15x
Gearing	147.19x
Moneyness	0.5667
Difference Strike	32.5 $
Difference Strike %	+43.33%
Spread	0.026 €
Spread %	65.00%
Theoretical value	0.0280
Implied Volatility	67.77 %
Total Loss Probability	97.17 %
Intrinsic value	0.000000
Present value	0.0280
Break even	75.30 €
Theta	-0.01x
Vega	0x
Rho	0x

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

42.5 USD

Average target price

53.19 USD

Spread / Average Target

+25.16%

Consensus